Skip to main content
Signal8

Zelira Therapeutics Limited (ZLDAF)

Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.

Sector: Biotechnology

Industry: Biotechnology

Zelira Therapeutics Limited logo

Zelira Therapeutics Limited

OTC:ZLDAFHealthcare
CLOSED
Mkt Cap-
EV-
Float12.56M
O/S13.15M
VOL1K sh
$ Vol$227
RVOL3.06×
Inst Own-
Net Cash/Sh-
Dilution
Short interest (FINRA)
Not computed yet: no FINRA short interest has been matched to this float.

Float 12.56M · FMP free float

1.1K
Oct 31 (382d)prev 498▲ 124.5%
4.49
Oct 31 (382d)prev 1.04▲ 331.7%
Borrow (IBKR)

The cost to borrow ZLDAF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver

No price or settlement history available to chart.

Off-exchange short volume

Too few published sessions to show a reading in context.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for ZLDAF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually